Global Biomarkers Market

In-vitro diagnostics devices and equipment is a gadget that tests human samples collected from the human body such as tissues and blood, with the goal of using the results to help with clinical diagnosis or management. The main types of in-vitro diagnostics equipment are point-of-care diagnostics devices and equipment, immunochemistry diagnostic devices and equipment, clinical chemistry diagnostics devices and equipment, molecular diagnostics devices and equipment, microbiology diagnostic devices and equipment, hemostasis diagnostic devices and equipment, hematology diagnostic devices, and equipment, and immunohematology diagnostic devices, and equipment. Hematology instruments are machines that analyze blood. The hematology instruments perform blood counts, detect proteins or enzymes, and help to diagnose illnesses or genetic defects. The type of expenditure is public and private. The products used are instruments/equipment and disposables. The end-users are hospitals and clinics, diagnostic laboratories, and others. The in-vitro diagnostics devices and equipment market research report is one of a series of new reports from The Business Research Company that provides in-vitro diagnostics devices and equipment market statistics, including in-vitro diagnostics devices and equipment industry global market size, regional shares, competitors with a in-vitro diagnostics devices and equipment market share, detailed in-vitro diagnostics devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the in-vitro diagnostics devices and equipment industry. This in-vitro diagnostics devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global in-vitro diagnostics market grew from $95.6 billion in 2022 to $106.53 billion in 2023 at a compound annual growth rate (CAGR) of 11.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The in-vitro diagnostics market is expected to grow to $148.58 billion in 2027 at a CAGR of 8.7%. Demand for point-of-care diagnostic devices is increasing as they provide rapid results, are cost-effective, and have advanced diagnosis features for patients. The number of patients seeking treatments at local physician offices, retail clinics, and in-patient homes is increasing thus boosting the demand for point-of-care testing devices. Companies in this market are focusing on developing more user-friendly, reliable, and efficient point of care devices. For instance, in March 2020, Abbott launched Novel COVID-19 Test. The test will be used on the m2000 RealTime system available in hospitals and molecular labs in the U.S. Philips also launched a new handheld blood test, Handheld Minicare I-20 system used for diagnosing heart attacks in emergency departments which provide results within 10 minutes. IVD devices are being integrated with IoT and data analytics technologies to improve device efficiency and increase device security. IoT refers to a system of interconnected devices via communication technologies such as WIFI and Bluetooth for data transfer and accessing devices remotely. Data analytics refers to qualitative and quantitative techniques, used to infer actionable information from large data sets. These technologies are helping in enhancing IVD device functionality, mainly through remote monitoring, predictive maintenance for decreased downtime, and advanced data processing capabilities. Major companies in the in-vitro diagnostics devices and equipment market include Siemens Healthineers, F. Hoffmann-La Roche Ltd., Danaher (Beckman Coulter Inc), Abbott Laboratories Inc., and Thermo Fisher Scientific Inc. North America was the largest region in the global in-vitro diagnostics market in 2022. Asia-Pacific was the second largest region in the global in-vitro diagnostics market. The regions covered in the in-vitro diagnostics devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the in-vitro diagnostics devices and equipment market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa., South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The in-vitro diagnostics devices and equipment market consist of sales of kits, reagents, piece of software, system, and instrument. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global in-vitro diagnostics market is segmented - 1) By Type: Point-of-Care Diagnostics Devices And Equipment, Immunochemistry Diagnostic Devices And Equipment, Clinical Chemistry Diagnostics Devices And Equipment, Molecular Diagnostics Devices And Equipment, Microbiology Diagnostic Devices And Equipment, Hemostasis Diagnostic Devices And Equipment, Hematology Diagnostic Devices And Equipment, Immunohematology Diagnostic Devices And Equipment 2) By End User: Hospitals And Clinics, Diagnostic Laboratories, Other End Users 3) By Type of Expenditure: Public, Private 4) By Product: Instruments/Equipment, Disposables

The scientific research and development services are responsible for conducting original research on a systematic basis to gain new knowledge and to apply research findings or other scientific knowledge to create new or improved products or processes. The main types of scientific research and development services are social sciences and humanities services; physical, engineering, and life sciences; nanotechnology services; and biotechnology services. Nanotechnology is the near-atomic manipulation of matter to create new structures, materials, and technologies. Many fields, including medical, consumer goods, energy, materials, and manufacturing, will benefit from the technology. The different sizes of enterprises include large enterprises, small and medium enterprises, and involve various modes such as online and offline. The scientific research and development services market research report is one of a series of new reports from The Business Research Company that provides scientific research and development services market statistics, including scientific research and development services industry global market size, regional shares, competitors with a scientific research and development services market share, detailed scientific research and development services market segments, market trends and opportunities, and any further data you may need to thrive in the scientific research and development services industry. This scientific research and development services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global scientific research and development services market grew from $817.06 billion in 2022 to $897.68 billion in 2023 at a compound annual growth rate (CAGR) of 9.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, surge in commodity prices, and supply chain disruptions, and affecting many markets across the globe. The scientific research and development service market is expected to grow from $1,254.27 billion in 2027 at a CAGR of 8.7%. The scientific research and development services market is expected to grow rapidly due to increasing lifestyle and chronic diseases. This is mainly due to unhealthy lifestyles, a growing ageing population, rising inactivity and obesity. According to the World Health Organization, chronic disease prevalence reached 57% globally in 2020. China and India together had about 193.4 million diabetic patients in 2019, and India is expected to have about 101 million diabetic patients by 2030. In the field of mental health, the World Health Organization predicts that one in every four people will be affected by a type of mental disorder such as depression, schizophrenia, or anxiety in the future. In response to this, national governments across the globe are rapidly increasing their medical research expenditure. For instance, China's medical research spending has increased and will reach $1 trillion in 2020. Therefore, increasing investment in medical research to treat chronic diseases is further driving the demand for scientific research and development services. The outbreak of COVID-19 disease (COVID-19) has acted as a restraint on the scientific research and development services market in 2020 as governments globally imposed lockdowns and restricted trade, thereby limiting the need for professional services. COVID-19 is an infectious disease with flu-like symptoms including fever, cough, and difficulty breathing. The virus was first identified in 2019 in Wuhan, Hubei province of the People’s Republic of China and has spread globally, including Western Europe, North America, and Asia. Steps by national governments to contain the transmission have resulted in a decline in economic activity with countries entering a state of "lock down." The outbreak has had a negative impact on businesses throughout 2020 and into 2021. However, it is expected that the scientific research and development services market will recover from the shock over the forecast period as it is a "black swan" event and not related to ongoing or fundamental weaknesses in the market or the global economy. 4D printing has evolved from 3D printing with the additional feature of changing the geometrical shape and mechanical properties, with time being integrated as an additional fourth dimension. One of the major drawbacks of 3D printing is that it can only take the shape in which it was originally made and is static and inanimate. With the latest development of 4D printing, objects can now be made with responsive materials with certain inherent properties that can change or transform in response to external stimuli. It has widespread applications in medical science, such as tissue regeneration in the biomedical field. For example, printed micro tissue from bio ink can undergo maturation via cellular coating to form functional tissue constructs such as engineered tissue constructs. Major biotechnology research companies using 4D bio printing technology include Poietis, Biolife4D, and Precise Bio. Major companies in the scientific research and development services market include IQVIA Holdings Inc., Battelle Memorial Institute, Defense Advanced Research Projects Agency, Lawrence Livermore National Laboratory LLC, Charles River Laboratories, Inc., Frog Design, Lawrence Berkeley National Lab, Jackson Laboratory, Piramal Group, and WuXi AppTec Co., Ltd. North America was the largest region in the scientific research and development services market in 2022. Asia-Pacific was the second largest region in the scientific research and development services market. The regions covered in the scientific research and development services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the scientific research and development services market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The scientific research and development services market consists of revenue earned by entities that engage in research and experimental development on a contract, consultancy, or outsourced basis. Scientific research and development services establishments undertake processes where human capital is the major input. They make available the knowledge and skills of their employees, often on an assignment basis, where an individual or team is responsible for the delivery of services to the client. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global scientific research and development services market is segmented - 1) By Type: Social Sciences And Humanities Services, Physical, Engineering, And Life Sciences, Nanotechnology Services, Biotechnology Services 2) By End User Size: Large Enterprise, Small and Medium Enterprise 3) By Mode: Online, Offline

Nuclear imaging devices and equipment are used in the diagnosis of diseases by using small amounts of radioactive substances in the patients and are used in a wide range of medical applications including cardiology, obstetrics/gynecology, vascular, urology, and other medical applications. The main product types in the nuclear imaging devices and equipment are SPECT systems, PET systems, and planar scintigraphy. The SPECT scan is used to capture the images and create 3D scanning. These are used for various applications such as oncology, cardiology, neurology, other applications (orthopedics, urology, thyroid-related disorders, and gastroenterology) that are used in hospitals, imaging centres, academic & research institutes, other end users (pharmaceutical/biotechnology companies and CROs). The nuclear imaging devices and equipment market research report is one of a series of new reports from The Business Research Company that provides nuclear imaging devices and equipment market statistics, including nuclear imaging devices and equipment industry global market size, regional shares, competitors with a nuclear imaging devices and equipment market share, detailed nuclear imaging devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the nuclear imaging devices and equipment industry. This nuclear imaging devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global nuclear imaging devices and equipment market size will grow from $4.02 billion in 2022 to $4.22 billion in 2023 at a compound annual growth rate (CAGR) of 5.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The nuclear imaging devices and equipment market size is expected to grow from $4.99 billion in 2027 at a CAGR of 4.3%. The nuclear imaging devices and equipment market is being driven by increasing incidences and prevalence of diseases such as cancer, heart disease, gastrointestinal, endocrine, and neurological disorders. Such diseases are diagnosed in relatively early stages by nuclear imaging equipment as compared to other equipment. For instance, according to the American Cancer Society 2020, in the United States, 1.8 million new cancer cases are diagnosed and 606,520 cancer deaths in the United States, many of which have been diagnosed by nuclear imaging devices and equipment. The nuclear imaging devices and equipment market is being restrained by strict regulations by the Nuclear Regulatory Commission (NRC) medical use. For instance, the NRC requires nuclear imaging equipment licensees to use and store radioactive materials to protect workers and common people by removing unwanted exposure, which has resulted in a relatively less number of nuclear imaging equipment being manufactured. Companies in the nuclear imaging devices and equipment market are using hybrid imaging technologies such as positron emission tomography/computed tomography (PET/CT), single-photon emission computed tomography/computed tomography (SPECT/CT), and positron emission tomography/magnetic resonance imaging (PET/MRI) for nuclear medical imaging. These hybrid systems provide precise images with better resolution and both morphological and physiological information in just one instance of testing. For instance, a SPECT/CT system for skeletal evaluation offers accurate localization and improves the specificity of information provided by CT. The Nuclear Regulatory Commission (NRC), USA regulates the manufacture and use of radioactive materials in nuclear imaging devices, as well as radiation therapy and research. It has agreements with 37 US states which allows them to regulate the use of certain radioactive materials by giving licenses to hospitals, clinics, and medical centres. The US-based Food and Drug Administration (FDA) also regulates products and procedures that are radiation-emitting. It reviews the safety and use of radiopharmaceuticals and machines like x-rays, which produce radiation but do not make or use radioactive material. In April 2020, TTG Imaging Solutions, LLC., a company operating in nuclear medicine equipment based in the United States acquired Nuclear Imaging Services and Molecular Imaging Specialists for an undisclosed amount. With this acquisition, The company wants to expand its portfolio in diagnostics imaging. Nuclear Imaging Services is a company operating in nuclear imaging based in texas and Molecular Imaging Specialists, a company operating in nuclear imaging devices and equipment based in the United States. Major players in the market are Toshiba Medical Systems Corporation, Neusoft Medical Systems Co., Ltd., SurgicEye GmbH, Siemens Healthineers, GE Healthcare, Mediso Medical Imaging Systems Ltd., Digirad Corporation, CMR Naviscan Corporation, DDD Diagnostics, and Philips Healthcare. Western Europe was the largest region in nuclear imaging devices and equipment market in 2022. North America was the second-largest region in nuclear imaging devices and equipment market. The regions covered in the nuclear imaging devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the nuclear imaging devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, the UK, the USA, and Australia. The nuclear imaging devices and equipment market consist of sales of SPECT (single-photon emission computed tomography) systems, hybrid PET systems, and planar scintigraphy imaging systems. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global nuclear imaging devices and equipment market is segmented - 1) By product type: SPECT systems, PET systems, Planar Scintigraphy, 2) By application: Oncology, Cardiology, Neurology, Other Applications (Orthopedics, Urology, Thyroid-related Disorders, and Gastroenterology) 3) By end user: Hospitals, Imaging Centers, Academic & Research Institutes, Other End Users (Pharmaceutical/Biotechnology Companies and CROs)

Acne drugs refer to medications that aid in the treatment of acne scarring, blackheads, whiteheads, and other more severe types of the condition. It functions either by treating bacterial infections or by lowering edoema and oil production. Usually, it takes four to eight weeks before prescription acne medications start to work. Your acne might not go away completely for several months or even years. The main types of acne drugs are inflammatory acne drugs and non-inflammatory acne drugs. Inflammatory acne drugs refer to the drugs that are used to treat inflammatory acne problems such as mild to moderate inflammatory acne. The various therapeutic classes include retinoids, antibiotics, salicylic acid, and benzoyl peroxide that are used by various end users such as hospitals and clinics, pharmacies and drug stores, and ambulatory surgical centers. The acne drugs market research report is one of a series of new reports from The Business Research Company that provides acne drugs market statistics, including acne drugs industry global market size, regional shares, competitors with an acne drugs market share, detailed acne drugs market segments, market trends and opportunities, and any further data you may need to thrive in the acne drugs industry. This acne drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global acne drugs market size will grow from $5.44 billion in 2022 to $5.74 billion in 2023 at a compound annual growth rate (CAGR) of 5.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global acne drugs market size is expected to grow to $6.90 billion in 2027 at a CAGR of 4.7%. An increase in the disposable income of people is one of the major drivers in the acne drug market. An increase in disposable income is usually due to an improved economy leading to increased wages and salaries and boosting healthcare expenditure. According to the Office For National Statistics (UK), in 2020, the average household disposable income in the UK was £30,800 ($37,830), an increase of 2.3% from 2019. The rise in disposable income and increased expenditure on facial care products is expected to continue, thereby driving the market in the forecast period. Acne drugs are a major problem worldwide, close to 90% of people suffer from some sort of acne drug. In America alone, close to 12 million people suffer from a severe acne drug problem, that can lead to scarring of the skin if left untreated, as a result, many people purchase Acne drug care drugs and products. The presence of alternatives for acne drug treatment is one of the restraints on the acne drug market. Due to the availability of multiple alternatives, patients tend to choose one amongst many options based on price, side effects, duration, and many more. This increases the competition and hence, the competition cuts down a significant portion of business for the acne drugs market. For example, some of the alternatives for acne drug treatment apart from acne drugs are Ayurveda, home remedies, laser and photodynamic therapy, and extraction of whiteheads and blackheads using special tools like needles and forceps. Combination therapy is the latest trend in the acne drug market. Combination therapy is the process of combining two drugs with different mechanisms of action, such combinations of medication have better efficacy and adherence when compared with monotherapy (the use of only a single drug by itself). The combination of a topical retinoid drug, which unclogs the pores, along with an antimicrobial drug, which is used to treat an infection is being used to treat acne drugs. Example of combination therapy includes Epiduo, Acanya, Ziana, and Benzamycin produced by Galderma, Allergan, Medicis, and Atrix respectively. The stringent regulations concerning the usage of drugs to treat Acne Drugs have an impact on the acne drug market. The regulations have become more stringent due to the various side effects and adverse events caused during treatment. In India, the Central Drugs Standard Control Organization (CDSCO) has issued a warning regarding the safety guidelines concerning the use of the oral drug, isotretinoin. The CDSCO has directed the states and union territories’ drug controllers to check the labelling of isotretinoin drugs and make end users aware of the serious birth defects the drug may cause. Further, the Subject Expert Committee (SEC) for Dermatology and Allergy has recommended that the drug should be sold only under the prescription of a dermatologist, manufacturers should provide a package insert in local languages, and retail pharmacies should maintain the details of retail sale of the drug. Hence, these strict guidelines and regulations would impact the growth of the acne drug market. In December 2021, Sanofi S.A., a France based pharmaceutical and healthcare company specialising in drug development and commercialization, acquired Origimm Biotechnology GmbH for an undisclosed amount. Through this acquisition, Sanofi increases its vaccine R&D pipeline, skin microbiome and skin immunology expertise, and treatment options for acne disease. And the product will reach the rest of Europe. Origimm Biotechnology GmbH is an Austria based pharmaceutical company pioneering in the identification of pathogenic skin microbiome components and skin disease-causing bacterial antigens. Major players in the acne drugs market are Allergan PLC., Galderma S.A., Valeant Pharmaceutical International Inc., Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services Inc., GlaxoSmithKline PLC., Bayer AG, Stiefel Laboratories Inc., Ranbaxy Laboratories Limited, Pfizer Inc., Sun Pharmaceutical Industries Limited, Mayne Pharma Group Limited, Mylan N.V., Cipher, Daiichi Sankyo Company, Ltd., Guthy-Renker LLC., Medicis Pharmaceutical Corporation, Foamix Pharmaceuticals, BioPharmX, In, Roche Holding AG, F. Hoffmann-la Roche Ltd., Anterios Inc., AndroScience, Oculus Innovative Sciences, Aqua Pharmaceuticals, Skinvisible Pharmaceuticals and Prestium Pharma Inc. North America was the largest region in the acne drugs market in 2022. The Middle East is expected to be the largest growing region in the global acne drugs market during the forecast period. The regions covered in the global acne drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the acne drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The acne drugs market consists of sales of retinoids, antibiotics, and diapsone. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global acne drugs market is segmented - 1) By Type: Inflammatory Acne Drugs, Non-Inflammatory Acne Drugs 2) By End User: Hospitals & Clinics, Pharmacies & Drug Stores, Ambulatory Surgical Centres 3) By Therapeutic Class: Retinoids, Antibiotics, Salicylic Acid, Benzoyl Peroxide

Dermatitis refer to the inhibitors that treat skin inflammation, which is characterised by itchy rashes on swollen and reddish skin, in the outer layer of the body. It is a general term that describes a common skin irritation. The main classes of drugs in dermatitis are corticosteroids, emollients/moisturizers, antihistamines, calcineurin inhibitors, antibiotics, immunomodulators, and interleukin inhibitors. Corticosteroids are a group of steroid hormones generated by vertebrates' adrenal cortex and are also synthetic equivalents of these hormones. The different routes of administration include topical, oral, and injectable and are used in cancer, blood disorders, chronic diseases, and infectious diseases. It is distributed through various channels such as hospitals, retail pharmacies, drug stores, and online or mail pharmacies. The dermatitis market research report is one of a series of new reports from The Business Research Company that provides dermatitis market statistics, including dermatitis industry global market size, regional shares, competitors with a dermatitis market share, detailed dermatitis market segments, market trends, and opportunities, and any further data you may need to thrive in the dermatitis industry. This dermatitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global dermatitis market size will grow from $6.46 billion in 2022 to $6.89 billion in 2023 at a compound annual growth rate (CAGR) of 6.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global dermatitis market size is expected to grow to $8.57 billion in 2027 at a CAGR of 5.6%. Growth in the atopic dermatitis market is primarily driven by the increasing global prevalence of the disease. The prevalence of dermatitis in children is estimated to be around 15-20% while it is 1-3% in adults. The rising cases of food allergies are adding to the prevalence of dermatitis which ultimately leads to the increase in demand for the medicines to cure this disease. For example, according to the allergy asthma network 2020, approximately 31.6 million people in the United States have some form of atopic dermatitis. The prevalence of atopic dermatitis globally in children have 15-20 percent and in adults have 1 to 3 percent. The strict government regulations are one of the restraints for the dermatitis drug market. Atopic Dermatitis (eczema) usually occurs at a very early stage (0-5 years). To find the efficacy and efficiency of the drug, it has to be tried on every type of patient. The effects of certain drugs in adults are quite different than in children, as a reasonable result of the clinical trial cannot be used for the production of drugs that will be served to the children. This hinders the research and requires more effort in clearing regulations set by FDA. For example, as the patient population is largely children, the FDA in its CFR Code Title 21, Part 50 Protection of Human Subjects, and subpart D has laid down guidelines for the additional safeguard for children in clinical investigation. The regulation complies with the Children’s Health Act of 2000 which requires all children subjected to clinical trials to be given additional protection. The dermatitis market has witnessed a trend of increasing mergers and acquisitions (M&As), done with the purpose of business expansion and increasing visibility. M&As are playing a significant role in today's world and are assumed to expand this market in the years to come. The vendors in this industry are focusing on collaboration and partnerships to expand their portfolios and improve their market presence. Companies are also strategically making M&As to reduce competition and increase the scalability of their businesses. For instance, in January 2020, Eli Lilly and Company, a US-based pharmaceutical company specializing in the discovery, development, manufacturing, and commercialization of human drugs, acquired Dermira, Inc. for an amount of $1.1 billion. Through this acquisition, Lebrikizumab, an innovative, experimental monoclonal antibody, has been added to the immunology pipeline and marketed dermatology medicines in the product portfolio of Eli Lilly for the treatment of moderate-to-severe atopic dermatitis in patients 12 years of age and older. Dermira, Inc. is a US-based biopharmaceutical company pioneering in the discovery and development of novel therapies for dermatology patients. The dermatitis drugs market is governed by several regulatory bodies that require the drug manufacturers to get approvals from the concerned authorities before launching their medicines into the market. Two such major regulatory bodies are PMDA (Japan) and CDSCO (India) which carry out quality checks before declaring the drugs suitable for consumption. PMDA reviews the products to ensure the safety, quality, and efficacy of pharmaceuticals and then approves the products that are suitable in every parameter. Similarly, CDSCO is the central drug authority that is responsible for the approval of new drugs in India. These tedious approval processes make the drugs more effective and safe, thereby having a positive impact on the dermatitis drugs market. Major players in the dermatitis market are LEO Pharma A/S, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A., Bayer HealthCare, Encore Dermatology Inc., Meda Pharmaceuticals, Allergan PLC. (Republic of Ireland) and Bristol-Myers Squibb. North America was the largest region in the dermatitis market in 2022. Middle East is expected to be the fastest-growing region in the global dermatitis market during the forecast period. The regions covered in the global dermatitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the dermatitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The dermatitis market consists of sales of Stasis dermatitis, atopic dermatitis, and irritant contact dermatitis. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global dermatitis market is segmented - 1) By Drug Class: Corticosteroids, Emollients/Moisturizers, Antihistamines, Calcineurin Inhibitors, Antibiotics, Immunomodulators, Interleukin Inhibitors 2) By Distribution Channel: Hospital, Retail Pharmacies, Drug Stores, Online Or Mail Pharmacies 3) By Route Of Application: Topical, Oral, Injectable 4) By Application: Cancer, Blood Disorders, Chronic Diseases, Infectious Diseases

Biologics Market Definition

The biologics market consists of sales of biologics and related services by entities (organizations, sole traders and partnerships) that produce biologics or biosimilars to treat and prevent various microbial diseases and cancers. The biologics market comprises companies manufacturing biological products that are derived from genetically modified proteins and human genes. Biologics products include a wide range of recombinant therapeutic proteins, gene therapy tissues, somatic cells, vaccines, and allergenics. Biologics products are subjected to various laws and regulations that deal with patenting, testing, safety, efficacy, and marketing. Biologics products are isolated from natural sources such as human, animal, and microorganisms by biotechnological methods and other cutting-edge technologies.

Small animal imaging (in-vivo) refers to the advanced imaging techniques for monitoring cellular activity, pharmacological effects that have been developed, and disease progression in live animals. The small animal imaging (in-vivo) is used to observe, define, and quantify normal and pathologic processes in living animal organs and tissues non-invasively. The main components of small animal imaging (in-vivo) are micro-MRI, optical imaging, nuclear imaging, and other components. Micro-MRI refers to a non-invasive technique that produces detailed 3-dimensional (3D) images of tissues without the use of harmful radiation. The various applications include monitoring treatment response, biodistribution, determining drug/target engagement, cancer cell detection, biomarkers, longitudinal studies, and epigenetics which are used in veterinary clinics, veterinary hospitals, and veterinary institutes and research centers. The small animal imaging(in-vivo)market research report is one of a series of new reports from The Business Research Company that provides small animal imaging(in-vivo)market statistics, including small animal imaging(in-vivo)industry global market size, regional shares, competitors with a small animal imaging(in-vivo)market share, detailed small animal imaging(in-vivo)market segments, market trends and opportunities, and any further data you may need to thrive in the small animal imaging(in-vivo)industry. This small animal imaging(in-vivo)market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global small animal imaging (in-vivo) market size grew from $2.28 billion in 2022 to $2.54 billion in 2023 at a compound annual growth rate (CAGR) of 11.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The small animal imaging (in-vivo) market size is expected to grow to $3.8 billion in 2027 at a CAGR of 10.6%. Growing expenditure for the healthcare sector is expected to propel the growth of the small animal imaging (in-vivo) market going forward. Healthcare expenditure refers to the overall cost of health care (including public and private expenditures) as a percentage of GDP. Rising healthcare expenditure and increasing healthcare awareness, encourage the concept of self-care management where PET equipment is used in techniques such as small animal imaging. For instance, according to data released by the Organisation for Economic Co-operation and Development, a France-based intergovernmental economic organization, in 2020 health spending as a share of GDP jumped to 9.7% across OECD countries, up from 8.8% in 2019. A group of 17 OECD countries suggests that health spending continued to grow strongly in 2021 by around 6%. Therefore, growing expenditure for the healthcare sector is driving the growth of the small animal imaging (in-vivo) market. Technological advancement is a key trend gaining popularity in the small animal imaging (in-vivo) market. Major companies operating in the small animal imaging (in vivo) market are focused on technological advancement to strengthen their position. For instance, in April 2022, PerkinElmer, Inc., a US-based company engaged in business areas such as diagnostics, life science research, and imaging, launched the Vega imaging system, an automated advanced technology ultrasound platform. The automated technology involves the use of two automated transducers, resulting in easy-to-use technology and generating more consistent results to visualize the pathophysiology of the disease. In August 2021, Rigaku Corporation, a Japan-based global manufacturer and distributor of scientific and industrial instrumentation primarily in X-ray and imaging technologies, acquired MILabs B.V. for an undisclosed amount. With this acquisition, Rigaku enlarged its global life sciences modality business by merging its original X-ray imaging business with MILabs' multi-modality businesses for animals, which included PET (Positron Emission Tomography), SPECT (Single Photon Emission Computed Tomography), Optical Imaging, and CT (Computed Tomography) equipment. MILabs B.V. is a Netherland-based company engaged in the development and manufacturing of molecular preclinical imaging systems such as SPECT, PET, CT, and optical imaging systems operating in small animal imaging(in-vivo). Major players in the market are Bruker, PerkinElmer, Miltenyi Biotec, Aspect Imaging Ltd., Mediso Ltd., LI-COR Biosciences, Life Technologies Corporation, Trifoil Imaging, Promega Corporation, New England Biolabs, MR Solutions Ltd., General Electric, Sofie Biosciences Inc., Biospace Lab, and Agilent Technologies Inc. North America was the largest region in the small animal imaging (in-vivo) market in 2022. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in small animal imaging (in-vivo) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the small animal imaging (in-vivo) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The small animal imaging (in-vivo) market includes revenues earned byPET, X-ray CT, MRI, and SPECT scanners. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global small animal imaging in vivo market is segmented - 1) By Component: Micro-MRI, Optical Imaging, Nuclear Imaging, Other Components 2) By Application: Monitoring Treatment Response, Bio Distribution, Determining Drug or Target Engagement, Cancer Cell Detection, Biomarkers, Longitudinal Studies, Epigenetics 3) By End User: Veterinary Clinics, Veterinary Hospitals, Veterinary Institutes and Research Centers

Renal biomarker refers to proteins, lipids, genes, metabolites, proteomic patterns, or cells that are found on a urinalysis that is employed to determine the glomerular filtration rate of the kidney, a drop in which indicates kidney damage. The renal biomarkers are used to estimate the nature and severity of kidney injury. The main types of biomarkers in renal biomarkers are functional biomarker, upregulated protein, and other biomarker types. Functional biomarkers refer to the biomarker that allows the diagnosis of kidney injury in individuals with normal kidney function, also in chronic kidney disease patients where the same injury would give rise to a significant decrease in functional biomarkers such as Cr. The different diagnostic techniques include enzyme-linked immunosorbent assay, particle-enhanced turbidimbiometric immunoassay (PETIA), colorimetric assay, and chemiluminescent enzyme immunoassay (CLIA), liquid chromatography-mass spectrometry (LS-MS). The applications include diagnosis and disease progression monitoring and research homecare and are used by hospitals, diagnostic laboratories, and other end users. The renal biomarker market research report is one of a series of new reports from The Business Research Company that provides renal biomarker market statistics, including renal biomarker industry global market size, regional shares, competitors with a renal biomarker market share, detailed renal biomarker market segments, market trends and opportunities, and any further data you may need to thrive in the renal biomarker industry. This renal biomarker market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global renal biomarkers market size grew from $1.07 billion in 2022 to $1.16 billion in 2023 at a compound annual growth rate (CAGR) of 8.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The renal biomarkers market size is expected to grow to $1.56 billion in 2027 at a CAGR of 7.7%. The rise in geriatric and paediatric renal patients is expected to propel the growth of the renal biomarkers market going forward. Geriatric renal patients refer to the elderly patients aged above 70 years with advanced chronic kidney disease (CKD). However, paediatric renal patients refer to the patients who are commonly diagnosed with renal disorder during childhood and young adulthood. Renal biomarkers help to evaluate the severity of renal injury in geriatric and paediatric renal patients. For instance, in March 2021, according to the data published by the Centers for Disease Control and Prevention, a US-based government administrative agency, nearly 37 million adults in the US have chronic renal disease and it is more prevalent in adults 65 years of age and older (38%). Therefore, the rise in geriatric and paediatric renal patients is driving the growth of the renal biomarkers market. Technological advancements have emerged as a key trend gaining popularity in the renal biomarkers market. Major players operating in the renal biomarkers sector is focused on developing innovative technologies to sustain their position in the market. For instance, In January 2021, RenalytixAI, a UK-based developer of artificial intelligence (AI) enabled clinical diagnostic solutions for kidney disease, partnered with DaVita to develop KidneyIntelX. KidneyIntelX is a diagnostic tool powered by artificial intelligence to help spot those at risk of renal disease or kidney failure. KidneyIntelX uses a machine-learning algorithm to produce a patient-specific risk assessment based on blood biomarkers and electronic medical information. In April 2021, Renalytix AI, a US-based biotechnology research company, partnered with the Joslin Diabetes Center to integrate new biomarkers for chronic kidney disease. Through this partnership, Renalytix can enhance the indicators already being collected by KidneyIntelX with a panel of novel biomarkers. KidneyIntelX evaluates the likelihood of adverse kidney outcomes in people with Type 2 diabetes and early kidney disease. Joslin Diabetes Center is a US-based diabetes research centre and diabetes clinic. Major players in the renal biomarkers market are Abbott Laboratories, BioPorto Diagnostics A/S, Roche Holding AG, Thermo Fisher Scientific, bioMérieux SA, Randox Laboratories, Siemens Healthineers, Beckman Coulter, Astute Medical Inc., Nexelis, Sphingotec GmbH, Bio-Rad Laboratories, Enzo Biochem Inc., PerkinElmer, and Novartis AG. North America was the largest region in the renal biomarkers market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the renal biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the renal biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The renal biomarker market consists of revenues earned by entities by providing renal biomarker services such as integrated drug discovery, phenotypic assay, custom services, in vivo, biomarker identification, glomerular filtration diagnosis. The market value includes the value of related goods sold by the service provider or included within the service offering. The renal biomarker market also includes sales of point-of-care kit, antibody screening, cell-based diagnostic devices which are used in providing renal biomarker services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global renal biomarkers market is segmented - 1) By Biomarker Type: Functional Biomarker, Up Regulated Protein, Other Biomarker Types 2) By Diagnostic Technique: Enzyme-Linked Immunosorbent Assay, Particle-Enhanced Turbidimetric Immunoassay (PETIA), Colorimetric Assay, Chemiluminescent Enzyme Immunoassay (CLIA), Liquid Chromatography Mass Spectrometry (LS-MS) 3) By Application: Diagnosis And Disease Progression Monitoring, Research Homecare 4) By End User: Hospitals, Diagnostic Laboratories, Other End Users